Who owns PRLD?
Institutional ownership of Prelude Therapeutics Incorporated from Form 13F, Q2 2026
75 institutional managers reported holding Prelude Therapeutics Incorporated (PRLD) in Form 13F filings for Q2 2026, with 49,599,407 shares worth $264M. The largest reported holder was Orbimed Advisors LLC. Managers that filed both quarters added a net 18,827,564 shares (+61.2%). 34 opened new positions and 13 sold out.
- Funds holding
- 75
- Value held
- $264M
- New / sold out
- 34 / 13
- Net shares, same filers
- +61.2%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of PRLD
Share of 13F holdings is each fund's shares as a share of the 49,599,407 PRLD shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Ra Capital Management, L.p. New+$34.5M
- Soleus Capital Management, L.P. New+$18.0M
- Orbimed Advisors LLC Added+$15.0M
- BlackRock, Inc. Added+$7.9M
- Kynam Capital Management, LP Added+$4.4M
- Vanguard Capital Management LLC Added+$4.2M
- Adage Capital Partners GP, L.l.c. New+$4.1M
- ADAR1 Capital Management, LLC Added+$4.0M
- Geode Capital Management, LLC Added+$2.9M
- Millennium Management LLC Added+$2.5M
Biggest sellers in Q2 2026
- EcoR1 Capital, LLC Sold out-$3.2M
- Susquehanna International Group, LLP Sold out-$916K
- Marshall Wace, LLP Trimmed-$897K
- Jane Street Group, LLC Sold out-$660K
- Goldman Sachs Group Inc Trimmed-$616K
- Citadel Advisors LLC Trimmed-$543K
- HRT Financial LP Sold out-$200K
- XTX Topco Ltd Sold out-$196K
- Bank of America Corp Trimmed-$174K
- Focus Partners Wealth Sold out-$171K
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $112M and sold $8.0M; 25 added and 8 trimmed.
Schedule 13D and 13G filings on PRLD
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-04-28RA CAPITAL MANAGEMENT, L.P. SCHEDULE 13G filed by Prelude Therapeutics IncorporatedSchedule 13G
- 2025-11-07INCYTE CORP SCHEDULE 13G filed by Prelude Therapeutics IncorporatedSchedule 13G
Questions about PRLD ownership
- Who owns PRLD stock?
- 75 institutional investment managers reported PRLD positions in their Form 13F filings for Q2 2026, holding 49,599,407 shares worth $264M in total. Orbimed Advisors LLC reported the largest position.
- Are funds buying or selling PRLD?
- In Q2 2026, 34 managers opened new PRLD positions, 25 added, 8 trimmed and 13 sold out. Managers that filed in both quarters added a net 18,827,564 shares.
- How current is this PRLD institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to PRLD by CUSIP. Options are left out. PRLD news and filings · PRLD insider trades · Top funds